Overview of Penam

Quick Facts

Property	Description
Active ingredient	Imipenem and Cilastatin
Form	Powder for solution (Parenteral)
Pharmacological class	Carbapenem Antibiotic / Dehydropeptidase Inhibitor
Common general purpose	Eradication of severe, often resistant, bacterial pathogens
Origin	Semi-synthetic

What is Penam and What Type of Drug is it?

Penam refers to a specialized, fixed-dose combination medicine containing the two active ingredients, Imipenem and Cilastatin. The primary component, Imipenem, is classified pharmacologically as a potent beta-Lactam antibiotic, belonging to the high-efficacy sub-group known as Carbapenems. This entity is a semi-synthetic derivative, structurally engineered with a unique bicyclic ring system that grants it stability against many bacterial enzymes that typically inactivate older antibiotics. This specialized structure ensures the drug is highly effective against a diverse and often resistant spectrum of bacterial pathogens. This dual-component formulation is clinically recognized for its necessity in therapeutic use, as Imipenem alone is not viable.

Composition and the Role of Cilastatin

The drug is supplied as a sterile powder for solution and is necessarily a combination product because Imipenem is highly susceptible to degradation by human enzymes. The critical secondary ingredient, Cilastatin, is a synthetic compound that functions as a dehydropeptidase inhibitor. Cilastatin prevents the rapid metabolism of Imipenem by the human enzyme renal Dehydropeptidase-I (DHP-I) located in the kidneys. The combined formulation, sometimes sold under commercial names like Primaxin, shares the same essential Imipenem/Cilastatin composition, which is required for effective parenteral administration.

The General Purpose of This Combination Medicine

The primary purpose is to ensure the rapid and reliable eradication of a very broad spectrum of severe, difficult-to-treat bacterial pathogens. For instance, the medicine may be used when treating a systemic infection where the microbial cause is suspected to be multi-drug resistant. This combination provides a high-level defense that can successfully neutralize acute infections, including those caused by strains resistant to common antibacterial agents. The stability conferred by Cilastatin allows Imipenem to exert its full antibacterial power across various tissues, achieving reliable therapeutic concentrations, which is pharmacologically essential for its high-stakes general application.

Regulatory References

What side effects are possible with Penam?

Possible Side Effects and Safety Information

The safety profile of Penam (Imipenem/Cilastatin) is established through formal regulatory documentation, which classifies adverse reactions by frequency and the body system affected.

Category	Regulatory Documentation Overview
Adverse Reaction Scope	Reactions are frequently documented in the Gastrointestinal and Nervous Systems, along with effects on the Skin and at the Injection Site.
Frequency Classification	Adverse events are formally classified as Common (e.g., nausea, vomiting, diarrhea, rash) or Uncommon (e.g., seizures, confusion, hypotension) based on incidence rates observed in clinical studies.
System-Organ Classes	Effects are officially grouped under categories such as Nervous System Disorders (e.g., seizures, dizziness) and Hepatobiliary Disorders (e.g., transient increases in liver enzymes).
Serious Adverse Reactions	Clinically significant events explicitly noted in regulatory labels include Seizures (convulsions), Anaphylaxis (severe hypersensitivity), and Pseudomembranous Colitis (a severe form of diarrhea).
Population-Specific Notes	The risk of seizures is documented as being higher in patients with pre-existing Central Nervous System disorders or Renal Impairment. Dosage adjustment is a noted safety constraint in cases of compromised renal function.
Safety Restrictions	The medicine is formally restricted for use in patients with a history of severe hypersensitivity to other beta-lactam antibiotics due to the potential for cross-sensitivity. Concomitant use with valproic acid is also constrained due to the risk of reduced seizure control.

Regulatory Safety Summary

The official safety profile systematically categorizes adverse reactions by frequency, distinguishing common events from less common but more serious reactions.
Explicit safety notes detail the constraints concerning patients with underlying CNS or renal issues, which require close monitoring as defined by regulatory bodies.
The labeling clearly documents high-level safety concerns, including serious systemic and gastrointestinal risks, as part of the established risk assessment for the drug.

The organization of these safety domains, from common gastrointestinal effects to population-specific CNS risks, strictly defines the official, non-advisory safety boundaries for the use of this antibiotic, as documented by government health authorities.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented manifestations and required emergency actions for overdose involving Imipenem and Cilastatin (Penam), based strictly on regulatory prescribing information.

Documented Overdose Manifestations

Overdose exposure may lead to severe Central Nervous System (CNS) manifestations, which are documented as an exaggeration of known adverse effects. Officially recognized signs include seizures and tremors, which are the most commonly reported neurological signs. Other documented presentations include drowsiness, nystagmus, emesis (vomiting), and tachycardia (rapid heart rate). Severe outcomes listed in regulatory documents include status epilepticus, coma, and potential respiratory arrest.

Emergency Actions and Management

Immediate medical attention must be sought for any suspected overdose event. Regulatory guidance mandates that emergency medical care is required immediately. Specific management is defined as symptomatic and supportive treatment. There is no specific antidote known for Imipenem or Cilastatin overdose. Haemodialysis is documented as a procedure that may be useful for the removal of the active drug components in severe cases. Intensive clinical monitoring, including Electrocardiogram (ECG) monitoring, is officially required.

Population-Specific Risk

Official labeling notes a particularly increased risk of seizures in patients with impaired renal function due to reduced drug clearance.

Therapeutic Uses of Penam

Management of Severe, Complicated Organ Infections

Penam (Imipenem/Cilastatin) is commonly used in clinical settings to manage severe, complicated bacterial infections that create noticeable physiological strain and involve major body systems. This application is used for conditions presenting with systemic or localized discomfort, such as complicated lower respiratory tract infections (like severe pneumonia), intra-abdominal infections (including abscesses), gynecologic infections, and bone and joint infections. This medication is considered relevant in the management of resistant strains.

Contextual Note: Relevant for Symptoms of Acute Systemic Sickness

Supportive Therapy for Multi-Drug Resistant Bacteria

The medication is often applied across therapeutic domains where additional symptomatic support is needed because the infection is caused by bacteria that are multi-drug resistant or difficult to treat with standard agents. Penam's activity may assist with maintaining functional stability during periods of heightened systemic burden. It is often used to provide support that helps ease the overall symptom load during difficult acute episodes.

Easing Acute Systemic Sickness and Discomfort

A key benefit is that it is relevant for easing acute symptoms related to systemic imbalance and inflammation, such as unrelenting high fever and chills, which are often signs of acute toxicity. Effective management of the infection contributes to easing the overall symptom load, which supports patients during episodes of heightened physiological activity.

Regulatory References

NIH DailyMed label

Eligibility and Restrictions for Use

Who Can and Cannot Use Penam?

Eligibility for Penam (Imipenem/Cilastatin) is strictly defined by regulatory criteria, focusing on patient history and physiological function. The medicine is contraindicated for individuals with known hypersensitivity to Imipenem, Cilastatin, any other Carbapenem, or a history of severe allergic reaction to any beta-Lactam antibiotic, such as penicillins or cephalosporins.

Use is generally established for adults and adolescents. In the pediatric population, eligibility begins at three months of age for specific non-CNS infections, but the drug is not recommended for the treatment of meningitis or in infants under one year old due to insufficient data.

Conditional use is mandatory for patients with severe renal impairment (Creatinine Clearance le 30 mL/min); the medicine is not recommended if renal function is severely limited ( CrCl le 15 mL/min) unless hemodialysis is initiated. Patients with a history of Central Nervous System disorders, including seizures, require cautious use. The medicine is restricted during pregnancy (Category C) and lactation, requiring a risk-benefit assessment.

What should I know about interactions with other medicines?

The official regulatory interaction profile for Imipenem/Cilastatin (Penam) focuses primarily on combinations that affect central nervous system activity and those that alter drug exposure.

Interaction Scope

Category	Official Regulatory Documentation
Medicinal product categories with documented interactions:	Anticonvulsants (e.g., Valproic Acid class), Probenecid, and other CNS-acting agents (e.g., Ciclosporin, Ganciclovir).
Specific interacting medicines (if explicitly listed):	Ganciclovir, Valproic Acid, Divalproex Sodium, Probenecid, Ciclosporin.
Mechanistic basis of interactions (only if stated in label):	Competition for renal tubular secretion (with Probenecid). Significant reduction of plasma concentrations of co-administered drug (with Valproic Acid).
Timing-based interaction rules (if applicable):	None explicitly stated as mandatory dose-spacing requirements in core regulatory labels.
Interaction-related restrictions:	Formal prohibition/contraindication for co-administration with Ganciclovir. Requirement for alternative anticonvulsant therapy is noted when co-administered with Valproic Acid/Divalproex Sodium.

Interaction Classifications (High-Level)

Classification	Official Regulatory Documentation
Interaction severity classification:	Contraindicated (Ganciclovir, Valproate class), Clinically Significant PK Interaction (Probenecid), Clinically Significant PD Interaction (Ciclosporin).
Regulatory basis:	FDA Prescribing Information, EMA Summary of Product Characteristics (SmPC).

Resulting Interaction Structure

Official Interaction Statements:

Co-administration with Ganciclovir is formally contraindicated due to a documented increased risk of generalized seizures.
Co-administration with Valproic Acid or Divalproex Sodium results in a significant decrease in Valproate plasma concentrations, leading to a documented loss of seizure control, necessitating alternative anticonvulsants.
Probenecid co-administration increases the plasma concentration and half-life of Imipenem by competing for renal tubular secretion.
Co-administration with Ciclosporin has been associated with an increased occurrence of Central Nervous System side effects, including seizures.

Connection to the overall interaction profile (2–4 sentences): The regulatory documents establish a profile primarily defined by contraindications and restrictions against certain anticonvulsants and antiviral agents due to a high risk of neurological toxicity or loss of therapeutic efficacy. The profile also includes a specific pharmacokinetic interaction that increases exposure of the active antibiotic component, all based strictly on evidence presented in government drug labels.

Mechanism of Action

The Dual Mechanism of Action

The mechanism of Penam involves a dual, cooperative system. The primary molecule, Imipenem, exerts its effect by forming a stable, covalent bond with bacterial Penicillin-Binding Proteins (PBPs), the enzymes necessary for completing the microbial cell wall's structural integrity. This specific blockade prevents the final cross-linking of peptidoglycan, resulting in rapid loss of osmotic pressure and inducing a bactericidal effect against susceptible bacteria.

The secondary component, Cilastatin, acts as a necessary enabling mechanism. It functions as a competitive inhibitor of the human enzyme Renal Dehydropeptidase-I (DHP-I), located in the kidney. By blocking DHP-I activity, Cilastatin prevents the premature hydrolytic inactivation of Imipenem, ensuring a high, sustained level of chemically active Imipenem is delivered systemically to the site of action. This co-operation bolsters the antibacterial mechanism.

Dosage and Administration Information

How to Use Imipenem and Cilastatin (Penam): Official Administration Guidelines

Imipenem and Cilastatin is a combination medication administered strictly via the parenteral route—either by intravenous (IV) infusion or, for some formulations, intramuscular (IM) injection. The medication is supplied as a sterile powder in a 1:1 ratio of Imipenem to Cilastatin, requiring reconstitution and dilution with an appropriate solution (such as 0.9% Sodium Chloride) before use.

Dosage and Schedule

Dosages are expressed based on the Imipenem component. For adults with normal kidney function (Creatinine Clearance ge 90 mL/min), common IV dosing regimens are 500 mg every 6 hours or 1 g every 8 hours, with a maximum total daily dose that should not exceed 4.0 g. The treatment course duration is determined by a healthcare provider and must be completed fully to ensure therapeutic effect.

Administration Requirements

Administration Detail	Official Requirement
IV Infusion Time	Doses le 500 mg must be infused over 20 - 30 minutes; doses > 500 mg over 40 - 60 minutes.
Renal Adjustment	Mandatory dose reduction is required for adult patients with reduced kidney function (CrCl < 90 mL/min).
Hemodialysis	For patients on hemodialysis, the dose should be administered immediately following the hemodialysis session.

Pediatric patients (ge 3 months) require weight-based dosing, typically 15 - 25 mg/kg every 6 hours. The administration rate may be slowed if nausea occurs during the infusion.

Recent Clinical Evidence

Research evidence / Overview of studies for Penam (Imipenem/Cilastatin)

Evidence for Use in Complicated Intra-Abdominal Infections (cIAIs)

Research for Penam has been conducted primarily through Randomized Controlled Trials (RCTs) and comparative studies, applied in studies examining outcomes related to severe abdominal infections. These trials have monitored hospitalized adult patients, often requiring surgical intervention. Researchers studied for outcomes related to systemic or functional imbalance, specifically looking at the rate of clinical response and the microbiological response (clearance of the causative bacteria).

What remains uncertain is how the observed outcomes relate to those of other established treatments, as some pivotal trials used comparators that are no longer standard of care. Additionally, research is limited in providing detailed insight into the long-term effects of the treatment or the persistence of the microbiological response.

Evidence for Use in Severe Lower Respiratory Tract Infections (LRTIs)

The evidence base for severe lung infections, such as hospital-acquired pneumonia, includes RCTs and multicenter observational cohort studies. These studies were evaluated in populations of critically ill adults, where the conditions are characterized by heightened symptoms. Research examined clinical response, focusing on the resolution of pneumonia signs, as well as the microbiological clearance of the pathogen. The research also explored short-term symptom changes and described the observed 30-day all-cause mortality rates.

A key limitation is that the research base is limited primarily to adult hospitalized patients; data for certain groups remain insufficient, particularly for pediatric populations with severe LRTIs. Also, the trial populations included wide variations in the severity of underlying illness, meaning that subgroup findings are uncertain when trying to define consistent patterns.

Research Gaps and Areas of Uncertainty

The evidence for Penam, while generally robust for its primary indications (cIAI, LRTI, cUTI), is not without limitations. For certain uses, such as bone or joint infections, sample sizes were modest, and comparative evidence is lacking against modern standard-of-care treatments. Furthermore, the evidence base for less common resistant pathogens remains insufficient, and long-term effects are not fully established across all indications. Findings describe group patterns, not personal outcomes, and research cannot predict whether an individual will experience the same patterns observed in the trials.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Penam (FAQ)

Q: How quickly does Penam start working after taking it?

A: According to official product information, the time required for the medicine to reach peak concentrations in the bloodstream is typically described as being approximately 30 minutes after the intravenous infusion is completed. Pharmacokinetic data indicates that the medicine's components have a half-life of about 1 hour in individuals with normal kidney function.

Q: Can Penam cause dizziness or affect driving?

A: Regulatory documentation notes that side effects involving the nervous system, such as dizziness, confusion, and somnolence (drowsiness), have been reported. These effects may impact an individual's ability to perform tasks that require mental alertness.

Q: What happens if I stop taking Penam suddenly?

A: Official information indicates that the full treatment course must be completed, as prescribed, to ensure the infection is cleared completely. The full treatment course must be completed, as prescribed, to ensure the infection is cleared completely.

Q: Do children or teenagers use Penam, and is it approved for them?

A: Official use is established for adolescents and children 3 months of age and older for specific, non-Central Nervous System infections. Regulatory documentation notes that the side effects and problems reported in children 12 years and older have not been reported to be different from those seen in adults.

Q: Are there restrictions on operating heavy machinery while using Penam?

A: Regulatory documentation notes side effects related to the nervous system, such as dizziness, confusion, and drowsiness. Due to the potential for these effects, individuals should exercise care regarding activities that require mental focus, such as operating heavy machinery.

Q: Is it necessary to take Penam with food?

A: Penam is a specialized medicine that is administered by intravenous (IV) infusion or intramuscular (IM) injection. Because it is an injectable medication and not a pill taken by mouth, its use is not dependent on administration in relation to food.

Q: Are there any specific foods or drinks to avoid while taking Penam?

A: Regulatory documents that describe interactions focus primarily on interactions with other medications. The official prescribing information does not list any specific foods or drinks that are formally prohibited while taking this medicine.

Q: Can I take Penam if I have high blood pressure?

A: High blood pressure (hypertension) is not listed as a formal contraindication for Penam. However, changes in blood pressure, including both hypertension (high blood pressure) and hypotension (low blood pressure), have been reported as side effects in official safety documentation.

Q: What is the risk of addiction or dependence with Penam?

A: Penam is a carbapenem antibiotic, and this class of medicine is not listed as a controlled substance by regulatory bodies. Consistent with its classification, the official labeling does not describe a risk of addiction or physical dependence.

Q: Is Penam safe for people over the age of 65?

A: Official documentation notes that while the medicine has not been studied specifically in older people compared to younger adults, it is not expected to cause different side effects or problems in the geriatric population.

Q: Are there different strengths of Penam available?

A: Yes, Penam is available in different strengths, which are always expressed as the 1:1 ratio of Imipenem to Cilastatin. Common available strengths include 250 mg-250 mg, 500 mg-500 mg, and 750 mg-750 mg.

Q: What is the evidence that Penam is effective for its labeled use?

A: Before authorization, regulatory authorities review data from clinical studies and determine if sufficient evidence of efficacy is provided for the medicine's approved indications. This evidence is the basis for the medicine's formal approval for use.

Q: How is Penam different from other similar treatments?

A: Penam is pharmacologically classified as a Carbapenem antibiotic, a high-efficacy class of antibiotics. The key difference is its unique dual composition, where the ingredient Cilastatin is intentionally added to prevent the breakdown of the antibiotic Imipenem by a human kidney enzyme.

Q: Is Penam safe to use during pregnancy?

A: Official labeling classifies Penam in Pregnancy Category C. This means that use is restricted during pregnancy, as information suggests a potential risk of damage to the unborn child, and a formal risk-benefit assessment is indicated.

Q: Does Penam cause weight gain or weight loss?

A: Changes in body weight, whether gain or loss, are not listed among the commonly reported or officially documented side effects in the regulatory prescribing information.

Q: Can I use Penam if I am currently breastfeeding?

A: Regulatory information indicates there are no adequate studies available to fully determine the risk to an infant when this medicine is used during breastfeeding. Due to the limited data, a risk-benefit assessment is indicated for use during lactation.

Q: Are there any known severe allergic reactions associated with Penam?

A: Yes, regulatory labels explicitly include serious and occasionally fatal hypersensitivity reactions, such as anaphylaxis, as clinically significant events that have been reported with this medicine. Due to this risk, the drug is contraindicated in patients with a history of severe allergies to certain antibiotics.

Q: What happens if I accidentally take two doses of Penam?

A: Official safety information notes that exceeding the recommended dosage, which includes accidental over-exposure, has been reported to increase the risk of Central Nervous System side effects. These potential side effects include seizures and confusional states.

Q: Does Penam have any known effects on mood or behavior?

A: Yes, regulatory documents list adverse reactions related to the Central Nervous System. These side effects can sometimes include changes in mood, confusion, agitation, restlessness, and somnolence (drowsiness).

Q: What is the half-life of Penam?

A: The half-life of both the Imipenem and Cilastatin components is officially described in pharmacokinetic studies as being approximately 1 hour in individuals with normal kidney function. This measure describes the time it takes for the concentration of the medicine in the blood to reduce by half.

Q: Are headaches a common side effect of Penam?

A: Yes, headache is listed in regulatory documentation as a common side effect of Penam. In clinical studies, common side effects were those reported in 1% to 10% of patients.

Q: Does Penam contain lactose or gluten?

A: The full list of non-active ingredients, or excipients, used in the formulation is described in the official prescribing information for the specific product. The full list of excipients is available in the official prescribing information for reference.

Q: Can Penam be used for pain management?

A: Penam is approved and indicated exclusively for the treatment of severe bacterial infections. Pain management is not one of its approved uses, and its primary purpose is the eradication of bacterial pathogens.

Q: Is Penam available over-the-counter?

A: No, Penam is a sterile injection product. It requires administration by a healthcare professional and is available exclusively by prescription.

Q: What if I am taking a blood thinner, can I still take Penam?

A: Regulatory documentation notes that anti-bacterial agents, including Penam, may increase the effects of orally administered blood thinners, such as warfarin. Regulatory documents describe that co-administration may indicate a need for closer monitoring.

Q: Do I need to store Penam in the refrigerator?

A: The unreconstituted powder for injection should be stored at controlled room temperature, which is typically between 20 C and 25 C. Once mixed into a solution, the medicine should be used quickly, and the solution must not be frozen.

Q: Can Penam affect my vision?

A: Official safety documentation reports that changes in vision, specifically blurred vision, have been reported as a less common side effect.

Q: Why are people talking about Penam and 'Cognitive Effect Y'?

A: This discussion is likely related to the fact that regulatory documentation notes Penam can be associated with Central Nervous System effects. These can include symptoms such as confusion, delirium, and somnolence (drowsiness), which fall under a broad category of cognitive changes.

How should Penam be stored and disposed of?

Official Storage and Disposal Requirements

The storage of Penam (Imipenem/Cilastatin) powder must comply with specific regulatory conditions. The unreconstituted vials require storage at Controlled Room Temperature (20 C to 25 C), and must be protected from moisture and kept in the original container. The medicine must always be kept out of the reach of children.

Once reconstituted, the solution's stability is short and dependent on the diluent; for instance, stability in 0.9% Saline is 4 hours at room temperature, and it must not be frozen. As a single-use product, any unused portion, whether expired or remaining after administration, must be disposed of according to local official requirements and is prohibited from being thrown into household waste or wastewater.

Penam